Active substance
Bumetanide
- SFDA 1
- US FDA 26
- Health Canada 2
- US price lines 3
- NHS prices 3
- WHO EML 2
- Safety 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| BURINEX TABLETS 1 MG | 1 mg | Tablet · Oral use | 20 Blister | SAR 10.60 | NCE · Prescription | Leo Pharma | Withdrawn by MAH · Not Marketed |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| BUMEX | 1MG; 0.5MG; 2MG | tablet · oral | VALIDUS PHARMS | Prescription | 28 Feb 1983 |
| BUMETANIDE | 0.25MG/ML | injectable · injection | SAGENT | Prescription | 27 Jan 1995 |
| BUMETANIDE | 0.5MG; 1MG; 2MG | tablet · oral | HERITAGE PHARMA | Prescription | 24 Apr 1995 |
| BUMETANIDE | 0.5MG; 1MG; 2MG | tablet · oral | SANDOZ | Prescription | 21 Nov 1996 |
| BUMETANIDE | 0.25MG/ML | injectable · injection | WEST-WARD PHARMS INT | Prescription | 30 Apr 2008 |
| BUMETANIDE | 0.5MG; 1MG; 2MG | tablet · oral | AMNEAL PHARMS CO | Prescription | 18 Oct 2017 |
| BUMETANIDE | 0.5MG; 1MG; 2MG | tablet · oral | UPSHER SMITH LABS | Prescription | 23 Jan 2018 |
| BUMETANIDE | 0.5MG; 1MG; 2MG | tablet · oral | ZYDUS PHARMS | Prescription | 30 Apr 2018 |
| BUMETANIDE | 0.5MG; 1MG; 2MG | tablet · oral | RISING | Prescription | 12 Dec 2019 |
| BUMETANIDE | 0.25MG/ML | injectable · injection | GLAND | Prescription | 26 May 2022 |
| BUMETANIDE | 0.25MG/ML | injectable · injection | MSN | Prescription | 4 Aug 2022 |
| BUMETANIDE | 0.5MG; 1MG; 2MG | tablet · oral | TARO | Prescription | 24 Jul 2023 |
| BUMETANIDE | 0.25MG/ML | injectable · injection | LUPIN | Prescription | 17 Sep 2024 |
| BUMETANIDE | 0.5MG; 1MG; 2MG | tablet · oral | APPCO | Prescription | 18 Sep 2024 |
| BUMETANIDE | 0.25MG/ML | injectable · injection | QILU PHARM HAINAN | Prescription | 19 Sep 2024 |
| BUMETANIDE | 0.5MG; 1MG; 2MG | tablet · oral | RUBICON RESEARCH | Prescription | 27 Dec 2024 |
| BUMETANIDE | 0.25MG/ML | injectable · injection | ASPIRO | Prescription | 27 Feb 2025 |
| BUMETANIDE | 0.5MG; 1MG; 2MG | tablet · oral | MANKIND PHARMA | Prescription | 3 Apr 2025 |
| BUMETANIDE | 0.5MG; 1MG; 2MG | tablet · oral | JUBILANT GENERICS | Prescription | 5 Aug 2025 |
| ENBUMYST | 0.5MG/SPRAY | spray · nasal | CORSTASIS THERAP | Prescription | 12 Sep 2025 |
| BUMETANIDE | 0.5MG; 1MG; 2MG | tablet · oral | MSN | Prescription | 5 Feb 2026 |
| BUMETANIDE | 0.25MG/ML | injectable · injection | ADAPTIS | Prescription | 26 Feb 2026 |
| BUMEX | 0.25MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | injectable · injection | VALIDUS PHARMS | Discontinued | 28 Feb 1983 |
| BUMETANIDE | 0.25MG/ML | injectable · injection | HOSPIRA | Discontinued | 31 Oct 1994 |
| BUMETANIDE | 0.25MG/ML | injectable · injection | HOSPIRA | Discontinued | 30 Oct 1997 |
1 more — full table
Canada Canada — marketed products (Health Canada)
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | BUMETANIDE 0.5 MG TABLET | $0.12883 | per EA | 23 Sep 2026 |
| US NADAC | BUMETANIDE 1 MG TABLET | $0.10789 | per EA | 23 Sep 2026 |
| US NADAC | BUMETANIDE 2 MG TABLET | $0.1819 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Bumetanide 1mg tablets | £5.75 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Bumetanide 1mg/5ml oral solution sugar free | £289.35 | 150 ml | 1 Oct 2026 |
| NHS Drug Tariff | Bumetanide 5mg tablets | £62.73 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 16. Diuretics · core
Therapeutic equivalent to furosemide for Anuria or oliguria; Therapeutic equivalent to furosemide for Oedema - 12.4. Medicines used in heart failure · core
Therapeutic equivalent to furosemide for Heart failure
Safety signals and safety-related labeling changes
- EMA PRAC 11 Jul 2024 PRAC signal: Toxic epidermal necrolysis and Stevens-Johnson syndrome
Action for MAH: update of the product information: Yes - EMA PRAC 7 Mar 2024 PRAC signal: Toxic epidermal necrolysis
Action for MAH: update of the product information: No
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.